Report Detail

Request for Sample of this report

Service & Software Global Large Molecule Drugs CDMO Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM4578523
    • |
  • 29 March, 2024
    • |
  • Global
    • |
  • 105 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Service & Software

According to our (Global Info Research) latest study, the global Large Molecule Drugs CDMO market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the Large Molecule Drugs CDMO industry chain, the market status of Biological Technology (Cell Line Development, Large Molecule Drug Substance Development), Clinical (Cell Line Development, Large Molecule Drug Substance Development), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Large Molecule Drugs CDMO.
Regionally, the report analyzes the Large Molecule Drugs CDMO markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Large Molecule Drugs CDMO market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Large Molecule Drugs CDMO market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Large Molecule Drugs CDMO industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Cell Line Development, Large Molecule Drug Substance Development).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Large Molecule Drugs CDMO market.
Regional Analysis: The report involves examining the Large Molecule Drugs CDMO market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Large Molecule Drugs CDMO market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Large Molecule Drugs CDMO:
Company Analysis: Report covers individual Large Molecule Drugs CDMO players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Large Molecule Drugs CDMO This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Biological Technology, Clinical).
Technology Analysis: Report covers specific technologies relevant to Large Molecule Drugs CDMO. It assesses the current state, advancements, and potential future developments in Large Molecule Drugs CDMO areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Large Molecule Drugs CDMO market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Large Molecule Drugs CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Cell Line Development
Large Molecule Drug Substance Development
Market segment by Application
Biological Technology
Clinical
Pharmaceutical
Others
Market segment by players, this report covers
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Large Molecule Drugs CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Large Molecule Drugs CDMO, with revenue, gross margin and global market share of Large Molecule Drugs CDMO from 2019 to 2024.
Chapter 3, the Large Molecule Drugs CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Large Molecule Drugs CDMO market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Large Molecule Drugs CDMO.
Chapter 13, to describe Large Molecule Drugs CDMO research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Large Molecule Drugs CDMO
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Large Molecule Drugs CDMO by Type
    • 1.3.1 Overview: Global Large Molecule Drugs CDMO Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Large Molecule Drugs CDMO Consumption Value Market Share by Type in 2023
    • 1.3.3 Cell Line Development
    • 1.3.4 Large Molecule Drug Substance Development
  • 1.4 Global Large Molecule Drugs CDMO Market by Application
    • 1.4.1 Overview: Global Large Molecule Drugs CDMO Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Biological Technology
    • 1.4.3 Clinical
    • 1.4.4 Pharmaceutical
    • 1.4.5 Others
  • 1.5 Global Large Molecule Drugs CDMO Market Size & Forecast
  • 1.6 Global Large Molecule Drugs CDMO Market Size and Forecast by Region
    • 1.6.1 Global Large Molecule Drugs CDMO Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Large Molecule Drugs CDMO Market Size by Region, (2019-2030)
    • 1.6.3 North America Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
    • 1.6.6 South America Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Large Molecule Drugs CDMO Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Patheon
    • 2.1.1 Patheon Details
    • 2.1.2 Patheon Major Business
    • 2.1.3 Patheon Large Molecule Drugs CDMO Product and Solutions
    • 2.1.4 Patheon Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Patheon Recent Developments and Future Plans
  • 2.2 Eurofins Scientific
    • 2.2.1 Eurofins Scientific Details
    • 2.2.2 Eurofins Scientific Major Business
    • 2.2.3 Eurofins Scientific Large Molecule Drugs CDMO Product and Solutions
    • 2.2.4 Eurofins Scientific Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Eurofins Scientific Recent Developments and Future Plans
  • 2.3 Samsung Biologics
    • 2.3.1 Samsung Biologics Details
    • 2.3.2 Samsung Biologics Major Business
    • 2.3.3 Samsung Biologics Large Molecule Drugs CDMO Product and Solutions
    • 2.3.4 Samsung Biologics Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Samsung Biologics Recent Developments and Future Plans
  • 2.4 Catalent, Inc.
    • 2.4.1 Catalent, Inc. Details
    • 2.4.2 Catalent, Inc. Major Business
    • 2.4.3 Catalent, Inc. Large Molecule Drugs CDMO Product and Solutions
    • 2.4.4 Catalent, Inc. Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Catalent, Inc. Recent Developments and Future Plans
  • 2.5 Rentschler Biopharma SE
    • 2.5.1 Rentschler Biopharma SE Details
    • 2.5.2 Rentschler Biopharma SE Major Business
    • 2.5.3 Rentschler Biopharma SE Large Molecule Drugs CDMO Product and Solutions
    • 2.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Rentschler Biopharma SE Recent Developments and Future Plans
  • 2.6 AGC Biologics
    • 2.6.1 AGC Biologics Details
    • 2.6.2 AGC Biologics Major Business
    • 2.6.3 AGC Biologics Large Molecule Drugs CDMO Product and Solutions
    • 2.6.4 AGC Biologics Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 AGC Biologics Recent Developments and Future Plans
  • 2.7 Recipharm AB
    • 2.7.1 Recipharm AB Details
    • 2.7.2 Recipharm AB Major Business
    • 2.7.3 Recipharm AB Large Molecule Drugs CDMO Product and Solutions
    • 2.7.4 Recipharm AB Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Recipharm AB Recent Developments and Future Plans
  • 2.8 Siegfried Holding AG
    • 2.8.1 Siegfried Holding AG Details
    • 2.8.2 Siegfried Holding AG Major Business
    • 2.8.3 Siegfried Holding AG Large Molecule Drugs CDMO Product and Solutions
    • 2.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Siegfried Holding AG Recent Developments and Future Plans
  • 2.9 FUJIFILM Diosynth Biotechnologies
    • 2.9.1 FUJIFILM Diosynth Biotechnologies Details
    • 2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
    • 2.9.3 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product and Solutions
    • 2.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
  • 2.10 Scorpius
    • 2.10.1 Scorpius Details
    • 2.10.2 Scorpius Major Business
    • 2.10.3 Scorpius Large Molecule Drugs CDMO Product and Solutions
    • 2.10.4 Scorpius Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Scorpius Recent Developments and Future Plans
  • 2.11 Ardena
    • 2.11.1 Ardena Details
    • 2.11.2 Ardena Major Business
    • 2.11.3 Ardena Large Molecule Drugs CDMO Product and Solutions
    • 2.11.4 Ardena Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Ardena Recent Developments and Future Plans
  • 2.12 Alcami
    • 2.12.1 Alcami Details
    • 2.12.2 Alcami Major Business
    • 2.12.3 Alcami Large Molecule Drugs CDMO Product and Solutions
    • 2.12.4 Alcami Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 Alcami Recent Developments and Future Plans
  • 2.13 Cytiva
    • 2.13.1 Cytiva Details
    • 2.13.2 Cytiva Major Business
    • 2.13.3 Cytiva Large Molecule Drugs CDMO Product and Solutions
    • 2.13.4 Cytiva Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 Cytiva Recent Developments and Future Plans
  • 2.14 Thermo Fisher Scientific
    • 2.14.1 Thermo Fisher Scientific Details
    • 2.14.2 Thermo Fisher Scientific Major Business
    • 2.14.3 Thermo Fisher Scientific Large Molecule Drugs CDMO Product and Solutions
    • 2.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Thermo Fisher Scientific Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Large Molecule Drugs CDMO Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Large Molecule Drugs CDMO by Company Revenue
    • 3.2.2 Top 3 Large Molecule Drugs CDMO Players Market Share in 2023
    • 3.2.3 Top 6 Large Molecule Drugs CDMO Players Market Share in 2023
  • 3.3 Large Molecule Drugs CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Large Molecule Drugs CDMO Market: Region Footprint
    • 3.3.2 Large Molecule Drugs CDMO Market: Company Product Type Footprint
    • 3.3.3 Large Molecule Drugs CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Large Molecule Drugs CDMO Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Large Molecule Drugs CDMO Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Large Molecule Drugs CDMO Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Large Molecule Drugs CDMO Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
  • 6.2 North America Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
  • 6.3 North America Large Molecule Drugs CDMO Market Size by Country
    • 6.3.1 North America Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
    • 6.3.2 United States Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
  • 7.2 Europe Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
  • 7.3 Europe Large Molecule Drugs CDMO Market Size by Country
    • 7.3.1 Europe Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 7.3.3 France Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Large Molecule Drugs CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Large Molecule Drugs CDMO Consumption Value by Region (2019-2030)
    • 8.3.2 China Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 8.3.5 India Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
  • 9.2 South America Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
  • 9.3 South America Large Molecule Drugs CDMO Market Size by Country
    • 9.3.1 South America Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Large Molecule Drugs CDMO Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Large Molecule Drugs CDMO Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Large Molecule Drugs CDMO Market Drivers
  • 11.2 Large Molecule Drugs CDMO Market Restraints
  • 11.3 Large Molecule Drugs CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Large Molecule Drugs CDMO Industry Chain
  • 12.2 Large Molecule Drugs CDMO Upstream Analysis
  • 12.3 Large Molecule Drugs CDMO Midstream Analysis
  • 12.4 Large Molecule Drugs CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Large Molecule Drugs CDMO. Industry analysis & Market Report on Large Molecule Drugs CDMO is a syndicated market report, published as Global Large Molecule Drugs CDMO Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Large Molecule Drugs CDMO market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,641.32
    		3,961.98
    		5,282.64
    		3,128.52
    		4,692.78
    		6,257.04
    		492,802.80
    		739,204.20
    		985,605.60
    		291,728.40
    		437,592.60
    		583,456.80
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo